MedTrace Logo

8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

NCT04885855 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 322

Last updated 2025-03-13

No results posted yet for this study

Summary

This is open-label, randomized, multicentre study to compare the efficacy and safety of the 8-week versus 12-week of SOF-RVD combination treatment for non-cirrhotic chronic hepatitis C patients.

All the recruited subjects will receive the treatment accordingly and be followed up for 24 weeks following the completion of treatment.

Conditions

  • Hepatitis C

Interventions

DRUG

Sofosbuvir 400 MG

Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)

DRUG

Ravidasvir 200mg

Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)

Sponsors & Collaborators

  • Muhammad Radzi Abu Hassan

    lead OTHER_GOV

Principal Investigators

  • Muhammad Radzi Abu Hassan, FRCP · Hospital Sultanah Bahiyah, Ministry of Health Malaysia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-23
Primary Completion
2023-12-29
Completion
2024-03-15

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04885855 on ClinicalTrials.gov